



Bibliographie générale

1. Adebamowo C., Bah-Sow O., Binka F. et al. Randomised controlled trials for Ebola : practical and ethical issues. *The Lancet*, 2014, Oct 13, Vol. 384, No. 9952 : 1423-1424.
2. Anoko J. La réparation de la malédiction générale suite à l'enterrement d'une femme enceinte avec le bébé dans le ventre. Une approche anthropologique pendant l'épidémie de la maladie à virus Ebola en Guinée. Disponible sur <https://f.hypotheses.org/wp-content/blogs.dir/2225/files/2015/01/La-r%C3%A9paration-de-la-mal%C3%A9diction-g%C3%A9n%C3%A9rale-Julienne-Anoko-2014-12-22.pdf>
3. Arranz J., Lundeby K.M., Hassan S. et al. Clinical features of suspected Ebola cases referred to the Moyamba ETC, Sierra Leone : challenges in the later stages of the 2014 outbreak. *BMC Infect Dis*, 2016 Jun 22, 16 : 308. doi : 10.1186/s12879-016-1609-9.
4. Bah E.I., Lamah M.C., Fletcher T. et al. Clinical presentation of patients with Ebola virus disease in Conakry, Guinea. *N Engl J Med*, 2015 Jan 1, 372 (1) : 40-7. doi : 10.1056/NEJMoa1411249.
5. Bai C.Q., Mu J.S., Kargbo D. et al. Clinical and virological characteristics of Ebola virus disease patients treated with Favipiravir (T-705). Sierra Leone, 2014. *Clin Infect Dis*, 2016 Nov 15, 63 (10) : 1288-1294.
6. Baize S. Réponse immune précoce et contrôle de l'infection par le virus Ebola. *Med Sc*, 1999, 10 : 1168-71.
7. Baize S., Pannetier D., Oestereich L. et al. Emergence of Zaire Ebola virus disease in Guinea. *N Engl J Med*, 2014, 371 : 1418-1425 October 9, 2014 DOI : 10.1056/NEJMoa1404505.
8. Barry M., Touré A., Traoré FA. et al. Clinical predictors of mortality in patients with Ebola virus disease. *Clin Infect Dis*, 2015 Jun 15, 60 (12) : 1821-4. doi : 10.1093/cid/civ202.
9. Barry M., Traoré FA., Sako FB. et al. Ebola outbreak in Conakry, Guinea : epidemiological, clinical, and outcome features. *Med Mal Infect*, 2014 Dec, 44 (11-12) : 491-4. doi : 10.1016/j.medmal.2014.09.009.
10. Bausch D.G. Sequelae after Ebola virus disease : even when it's over it's not over. *Lancet Infect Dis*, 2015, Aug, 15 (8) : 865-6. doi : 10.1016/S1473-3099 (15) 70165-9.
11. Bausch D.G., Schwarz L. Outbreak of Ebola virus disease in Guinea : where ecology meets economy. *PLoS Neglected Tropical Diseases*, 2014, 8 : e3056.
12. Bolay F. A Randomized Controlled Trial of the Safety and Immunogenicity of Two Ebola Vaccines. Conférence CROI, Boston, février 2016.
13. Bwaka M.A., Bonnet M.-J., Calain P. et al. Ebola hemorrhagic fever in Kikwit, Democratic Republic of the Congo : clinical observations in 103 patients. *J Infect Dis*, 1999 fév., 179 Suppl 1 : S1-7.
14. CDC. *Outbreaks Chronology : Ebola Virus Disease*. 2017. <http://www.cdc.gov/vhf/ebola/outbreaks/history/chronology.html>
15. Calain P., Poncin M. Reaching out to Ebola victims : Coercion, persuasion or an appeal for self-sacrifice? *Soc Sci Med*, 2015, Dec, 147 : 126-33. doi : 10.1016/j.socscimed.2015.10.063.
16. Cauchemez S., Boëlle P.-Y., Thomas G., Valleron A.-J. Estimating in real time the efficacy of measures to control emerging communicable diseases. *American Journal of Epidemiology*, 2006, 164 : 591-7.
17. Centers for Disease Control and Prevention (CDC). *Flambée d'Ebola en Afrique de l'Ouest en 2014. Décompte des cas*. CDC, 2016.
18. Chowell G., Nishiura H. Transmission dynamics and control of Ebola virus disease (EVD) : a review. *BMC medicine*, 2014, 12 : 196.
19. Clark D.V., Kibuuka H., Millard M. et al. Long-term sequelae after Ebola virus disease in Bundibugyo, Uganda : a retrospective cohort study. *Lancet Infect Dis*, 2015, Aug, 15 (8) : 905-12. doi : 10.1016/S1473-3099 (15) 70152-0. PubMed PMID : 25910637.
20. Cox E., Borio L., Temple R. Evaluating Ebola therapies : the case for RCTs. *The New England Journal of Medicine*, 2014, 371 : 2350-1.
21. Dallatomasina S., Crestani R., Sylvester Squire J. et al. Ebola outbreak in rural West Africa : epidemiology, clinical features and outcomes. *Trop Med Int Health*, 2015 Apr, 20 (4) : 448-54. doi : 10.1111/tmi.12454. PubMed PMID : 25565430
22. Deen G.F., Knust B., Broutet N. et al. Ebola RNA persistence in semen of Ebola virus disease survivors : Preliminary report. *N Engl J Med*, 2015 : doi : 10.1056/NEJMoa1511410.
23. Delfraissy J.-F., Yazdanpanah Y., Levy Y. REACTing : the French response to infectious disease crises. *The Lancet*, 2016, May 1, Vol. 387, No. 10034 : 2183-2185.
24. Diallo B., Sissoko D., Loman N.J. et al. Resurgence of Ebola virus disease in Guinea linked to a survivor with virus persistence in seminal fluid for more than 500 days. *Clin Infect Dis*, 2016, Nov 15, 63 (10) : 1353-1356.
25. Dunning J., Kennedy S.B., Antierens A. et al. Experimental treatment of Ebola virus disease with Brincidofovir. *PLoS One*, 2016, 11 (9) : 1-10.
26. Dunning J., Sahr F., Rojek A. et al. Experimental treatment of Ebola virus disease with TKM-130803 : A single-arm phase 2 clinical trial. *PLoS Med*, 2016, 13 (4) : 1-19.
27. Dörnemann J., Burzio C., Ronsse A. et al. First newborn baby to receive experimental therapies survives Ebola virus disease. *J Infect Dis*, 2017, 215 : jiw493.
28. Ebola haemorrhagic fever in Zaire, 1976. *Bulletin of the World Health Organization*, 1978, 56 : 271-93.
29. Eggo R.M., Watson C.H., Camacho A. et al. Duration of Ebola virus RNA persistence in semen of survivors : population-level estimates and projections. *Euro Surveill*, 2015, 20 : 30083.
30. Epelboin A. *Approche anthropologique de l'épidémie de FHV Ebola 2014 en Guinée Conakry*. Rapport de mission OMS mars-avril 2014 : 34 p. <https://hal.archives-ouvertes.fr/hal-01090291>.
31. Epstein L., Wong K.K., Kallen A.J., Uyeki T.M. Post-Ebola signs and symptoms in U.S. survivors. *NEJM*, 2015, 373 (25) : 2484-2486. DOI : 10.1056/NEJMc1506576.
32. Etard J.F., Sow M.S., Leroy S. et al. Postebogui Study Group. Multidisciplinary assessment of post-Ebola sequelae in Guinea (Postebogui) : An observational cohort study. *Lancet Infect Dis*, 2017, Jan 13. pii : S1473-3099 (16) 30516-3. doi : 10.1016/S1473-3099 (16) 30516-3.
33. Fallah M.P., Prevail III Research Team. A cohort study of survivors of Ebola virus infection in Liberia (PREVAIL III). Annual Conference on Retroviruses and Opportunistic Infections, Boston, MA, Feb 22-25, 2016. 74LB.

34. Faye O., Andronico A., Faye O. *et al.* Use of viremia to evaluate the baseline case fatality ratio of Ebola virus disease and inform treatment studies : a retrospective cohort study. *PLoS Medicine*, 2015, 12 : e1001908.
35. Faye O., Boëlle P.-Y., Heleze E. *et al.* Chains of transmission and control of Ebola virus disease in Conakry, Guinea. In 2014: An observational study. *The Lancet Infectious diseases*, 2015, 15 : 320-6.
36. Formenty P., Leroy E.M., Epelboin A. *et al.* Detection of Ebola virus in oral fluid specimens during outbreaks of Ebola virus hemorrhagic fever in the Republic of Congo. *Clin Infect Dis*, 2006, 42 : 1521-26.
37. Gignoux E., Azman A.S., de Smet M. *et al.* Effect of artesunate-amodiaquine on mortality related to Ebola virus disease. *N Engl J Med*, 2016, 374 (1) : 23-32.
38. Gire S.K., Goba A., Andersen K.G. *et al.* Genomic surveillance elucidates Ebola virus origin and transmission during the 2014 outbreak. *Science*, 2014, 345 : 1369-72.
39. Haaskjold Y.L., Bolkan H.A., Krogh K.Ø. *et al.* Clinical features of and risk factors for fatal Ebola virus disease, Moyamba District, Sierra Leone, December 2014-February 2015. *Emerg Infect Dis*, 2016 Sept, 22 (9) : 1537-44. doi : 10.3201/eid2209.151621.
40. Henao-Restrepo A.M., Camacho A., Longini I.M. *et al.* Efficacy and effectiveness of an rVSV-vectored vaccine in preventing Ebola virus disease : Final results from the Guinea ring vaccination, open-label, cluster-randomised trial (Ebola Ça Suffit!). *Lancet*, 2016 : 1-14.
41. Henao-Restrepo A.M., Longini I.M., Egger M. *et al.* Efficacy and effectiveness of an rVSV-vectored vaccine expressing Ebola surface glycoprotein : interim results from the Guinea ring vaccination cluster-randomised trial. *Lancet*, 2015, 386 : 857-66.
42. Howlett P., Brown C., Helderman T. *et al.* Ebola virus disease complicated by late-onset encephalitis and polyarthritis, Sierra Leone. *Emerg Infect Dis*, 2016, 22 (1) : 150-152.
43. Jacobs M., Rodger A., Bell D.J. *et al.* Late Ebola virus relapse causing meningoencephalitis: A case report. *Lancet*, 2016, Jul 30, 388 (10043) : 498-503. doi : 10.1016/S0140-6736 (16) 30386-5.
44. Janvier F., Foissaud V., Delaune D. *et al.* Deployment of the french military field laboratory dedicated to Ebola virus infected patients in Guinea, January-July 2015. *J Infect Dis*, 2016, 213 : 1208-9.
45. Ji Y.J., Duan X.Z., Gao X.D. *et al.* Clinical presentations and outcomes of patients with Ebola virus disease in Freetown, Sierra Leone. *Infect Dis Poverty*, 2016 Nov 3, 5 (1) : 101.
46. Kibadi K., Mupapa K., Kuvula K. *et al.* Late ophthalmologic manifestations in survivors of the 1995 Ebola virus epidemic in Kikwit, Democratic Republic of the Congo. *J Infect Dis*, 1999, 179 (suppl 1) : S13-14.
47. Legrand J., Grais R.-F., Boëlle P.-Y., Valleron A.-J., Flahault A. Understanding the dynamics of Ebola epidemics. *Epidemiology and Infection*, 2007, 135 : 610-21.
48. Leligidowicz A., Fischer W.A. 2nd, Uyeki T.M. *et al.* Ebola virus disease and critical illness. *Crit Care*, 2016 Jul 29, 20 (1) : 217.
49. Leroy E.M., Baize S., Lu C.Y. *et al.* Diagnosis of Ebola haemorrhagic fever by RT-PCR in an epidemic setting. *J Med Virol*, 2000, 60 (4) : 463-7.
50. MacNeil A., Farnon E.C., Wamala J. *et al.* Proportion of deaths and clinical features in Bundibugyo Ebola virus infection, Uganda. *Emerg Infect Dis*, 2010 Dec, 16 (12) : 1969-72. doi : 10.3201/eid1612.100627.
51. Mate S.E., Kugelman J.R., Nyenswah T.G. *et al.* Molecular evidence of sexual transmission of Ebola virus. *N Engl J Med*, 2015, 373 : 2448-54.
52. Mattia J.G., Vandy M.J., Chang J.C. *et al.* Early clinical sequelae of Ebola virus disease in Sierra Leone : a cross-sectional study. *Lancet Infect Dis*, 2016, Mar, 16 (3) : 331-8. doi : 10.1016/S1473-3099 (15) 00489-2.
53. Maugey N., Merens A., Quentin B. *et al.* Conception, déploiement, architecture et fonctionnement du centre de traitement des soignants. *Médecine et armées*, 2016, 44 : 161-68.
54. McElroy A.K., Erickson B.R., Flietstra T.D. *et al.* Ebola hemorrhagic fever : novel biomarker correlates of clinical outcome. *J Infect Dis*, 2014, 210 : 558-66.
55. Migliani R. Bilan de l'épidémie de maladie à virus Ebola en Guinée. Manifestation «Tropiques en marche». Aubusson, 8 mai 2016. Disponible sur <http://www.espace-jamot.fr>.
56. Milligan I.D., Gibani M.M., Sewell R. *et al.* Safety and immunogenicity of novel adenovirus type 26 and modified vaccinia Ankara-vectored Ebola vaccines : A randomized clinical trial. *Jama*, 2016, 315 (15) : 1610-23.
57. Mohammed H., Vandy A.O., Stretch R. *et al.* Sequelae and other conditions in Ebola virus disease survivors, Sierra Leone, 2015. *Emerg Infect Dis*, 2017, Jan, 23 (1) : 66-73. doi : 10.3201/eid2301.160631.
58. Moulin A.-M. dir. Back to the future. Les essais vaccinaux contre Ebola, au regard de l'histoire des résistances à l'immunisation. *Bull Soc Pathol Exot*, 2016. DOI 10.1007/s13149-016-0520-3.
59. Moulin A.-M. dir. L'anthropologie au défi de l'Ebola. *Anthropologie & Santé*, nov. 2015. Disponible sur <http://anthropologiesante.revues.org>
60. Murgue B., Delfraissy J.-F. Recherches en situation d'émergence infectieuse : la réponse à la crise se prépare dans l'intercriste. *Virologie*, 2012, 16 : 3-5.
61. Ndambi R., Akamituna P., Bonnet M.-J. *et al.* Epidemiologic and clinical aspects of the Ebola virus epidemic in Mosango, Democratic Republic of the Congo, 1995. *J Infect Dis*, 1999 Feb, 179 Suppl 1 : S8-10.
62. OMS. Les Origines de l'épidémie d'Ebola 2014. OMS, 2015. Disponible sur <http://www.who.int/csr/disease/ebola/one-year-report/virus-origin/fr/>.
63. Paessler S., Walker D.H. Pathogenesis of the viral hemorrhagic fevers. *Annu Rev Pathol*, 2013, 8 : 411-40.
64. Palich R., Gala J.-L., Petitjean F., Augier A. *et al.* A 6-year-old child with severe Ebola virus disease : Laboratory-guided clinical care in an Ebola treatment center in Guinea. *PLoS Negl Trop Dis*, 2016, Mar 24, 10 (3) : e0004393. doi : 10.1371.
65. Palich R., Gala J.L., Petitjean F. *et al.* A 6-year-old child with severe Ebola virus disease : Laboratory-guided clinical care in an Ebola treatment center in Guinea. *PLoS Negl Trop Dis*, 2016, 10 (3) : 10-14.
66. Panning M., Laue T., Ölschlager S. *et al.* Diagnostic reverse-transcription polymerase chain reaction kit for filoviruses based on the strain collections of all European biosafety level 4 laboratories. *The Journal of Infectious Diseases*, 2007, 196 (suppl_2) : S199-S204.
67. Penttilä I.A., Harris R.J., Storm P. *et al.* Cytokine dysregulation in the post-Q-fever fatigue syndrome. *QJM*, 1998, 91 : 549-60.



Bibliographie générale (suite)

68. Poletto C., Gomes M.F., Pastore y Piontti A. *et al.* Assessing the impact of travel restrictions on international spread of the 2014 West African Ebola epidemic. *Euro surveillance : Bulletin européen sur les maladies transmissibles*, 2014, 19.
69. Qureshi A.I., Chughtai M., Loua T.O. *et al.* Ebola virus disease survivors study in Guinea. *Clin Infect Dis*, 2015, 61 : 1035-42.
70. Rieger T., Kerber R., El Halas H. *et al.* Evaluation of RealStar reverse transcription : polymerase chain reaction kits for filovirus detection in the laboratory and field. *The Journal of Infectious Diseases*, 2016, 214 (suppl_3) : S243-S9.
71. Rivière A.-M., Feuillet C., Moreau N., Damène F., Rapp C. Maladie à virus Ebola et établissement de santé référent habilité. *Rev Infirm*, 2015, 212 : 17-9.
72. Rodriguez L.L., De Roo A., Guimard Y. *et al.* Persistence and genetic stability of Ebola virus during the outbreak in Kikwit, Democratic Republic of the Congo, 1995. *J Infect Dis*, 1999, 179 (suppl) : S170-76.
73. Rollin P.E., Bausch D.G., Sanchez A. Blood chemistry measurements and D-dimer levels associated with fatal and nonfatal outcomes in humans infected with Sudan Ebola virus. *J Infect Dis*, 2007, 196 (suppl 2) : S364-71.
74. Rowe A.K., Bertolli J., Khan A.S. *et al.* Clinical, virologic, and immunologic follow-up of convalescent Ebola hemorrhagic fever patients and their household contacts, Kikwit, Democratic Republic of the Congo. *Commission de Lutte contre les Epidémies. Kikwit. J Infect Dis*, 1999, 179 (suppl 3) : S28-35.
75. Saliou S.M., Etard J.F., Baize S. *et al.* New evidence of long-lasting persistence of Ebola virus genetic material in semen of survivors. *Clin Infect Dis*, 2016, 214 : 1475-76.
76. Sands P. *et al.* The neglected dimension of global security. A Framework for countering infectious-disease crises. *The New England Journal of Medicine*, 2016, 374 : 1281-7.
77. Santos E., Boavida J.E., Barroso A. *et al.* Late osteoarticular lesions following meningococemia with disseminated intravascular coagulation. *Pediatr Radiol*, 1989, 19 : 199-202.
78. Schieffelin J.S., Shaffer J.G., Goba A. *et al.* KGH Lassa Fever Program. ; Viral Hemorrhagic Fever Consortium. ; WHO Clinical Response Team. Clinical illness and outcomes in patients with Ebola in Sierra Leone. *N Engl J Med*, 2014, 371 : 2092-100.
79. Scott J.T., Semple M.G. Ebola virus disease sequelae : a challenge that is not going away. *Lancet Infect Dis*, 2017, Jan 13. pii : S1473-3099 (17) 30027-0. doi : 10.1016/S1473-3099 (17) 30027-0.
80. Seytre B. Time to change Ebola communication. *Letter to African Affairs*, 2015, Nov 19. Disponible sur <http://afraf.oxfordjournals.org/letters/114/454/136#123>
81. Sissoko D., Laouenan C., Folkesson E. *et al.* Experimental treatment with Favipiravir for Ebola virus disease (the JIKI Trial) : A historically controlled, single-arm proof-of-concept trial in Guinea. *PLoS Medicine*, 2016, 13 : e1001967.
82. Smit M.A., Michelow I.C., Glavis-Bloom J. *et al.* Characteristics and outcomes of pediatric patients with Ebola virus disease admitted to treatment units in Liberia and Sierra Leone : a retrospective cohort study. *Clin Infect Dis*, 2017 Feb 1, 64 (3) : 243-249. doi : 10.1093/cid/ciw725.
83. Soka M.J., Choi M.J., Baller A. *et al.* Prevention of sexual transmission of Ebola in Liberia through a national semen testing and counselling programme for survivors : An analysis of Ebola virus RNA results and behavioural data. *Lancet Glob Health*, 2016, 4 : e736-43
84. The PREVAIL II Writing Group for the M-NPIST. A randomized, controlled trial of ZMapp for Ebola virus infection. *N Engl J Med*, 2016, 375 (15) : 1448-56.
85. Thorson A., Formenty P., Lofthouse C., Broutet N. Systematic review of the literature on viral persistence and sexual transmission from recovered Ebola survivors : evidence and recommendations. *BMJ Open* 2016, 6 : e008859.
86. Tiffany A., Vetter P., Mattia J. *et al.* Ebola virus disease complications as experienced by survivors in Sierra Leone. *Clin Infect Dis*, 2016, 62 (11) : 1360-6.
87. Uyeki T.M., Erickson B.R., Brown S. *et al.* Ebola virus persistence in semen of male survivors. *Clin Infect Dis*, 2016, 62 : 1552-1555. doi : 10.1093/cid/ciw202 PMID : 27045122
88. Uyeki T.M., Mehta A.K., Davey R.T. Jr, *et al.* Working Group of the U.S. – European Clinical Network on Clinical Management of Ebola Virus Disease Patients in the U.S. and Europe. Clinical Management of Ebola Virus Disease in the United States and Europe. *N Engl J Med*, 2016 Feb 18, 374 (7) : 636-46.
89. van Griensven J., Bah E.I., Haba N. *et al.* Electrolyte and metabolic disturbances in Ebola patients during a clinical trial, Guinea, 2015. *Emerg Infect Dis*, 2016, 22 (12) : 2120-7.
90. van Griensven J., Edwards T., de Lamballerie X. *et al.* Evaluation of convalescent plasma for Ebola virus disease in Guinea. *N Engl J Med*, 2016, 374 (1) : 33-42.
91. Varkey J.B., Shantha J.G., Crozier. *et al.* Persistence of Ebola virus in ocular fluid during convalescence. *N Engl J Med*, 2015, 372 : 2423-2427. doi : 10.1056/NEJMoa1500306 PMID : 25950269
92. Vetter P., Fischer W.A., Schibler M. *et al.* Ebola virus shedding and transmission : review of current evidence. *J Infect Dis*, 2016, 214 : S177-84.
93. WHO Ebola Response Team, Agua-Agum J., Ariyaratna A. *et al.* West African Ebola epidemic after one year : slowing but not yet under control. *The New England Journal of Medicine*, 2015, 372 : 584-7.
94. WHO Ebola Response Team. Ebola virus disease in West Africa : the first 9 months of the epidemic and forward projections. *The New England Journal of Medicine*, 2014, 371 : 1481-95.
95. WHO. Ebola hemorrhagic fever in Sudan, 1976. Report of a WHO/International Study Team. *Bull World Health Organ*, 1978, 56 : 247-70.
96. WHO. Ebola hemorrhagic fever in Zaire, 1976. *Bull World Health Organ*, 1978, 56 : 271-93.
97. WHO. Ebola hemorrhagic fever. *Wkly Epidemiol Rec*, 1995, 70 : 241-2.
98. Wendo C. Caring for the survivors of Uganda's Ebola epidemic one year on. *Lancet*, 2001, 358 : 1350.
99. Wesolowski A., Buckee C.O., Bengtsson L., Wetter E., Lu X., Tatem A.J. Commentary : containing the Ebola outbreak : the potential and challenge of mobile network data. *PLoS Currents*, 2014, 6.
100. Xu Z., Jin B., Teng G. *et al.* Epidemiologic characteristics, clinical manifestations, and risk factors of 139 patients with Ebola virus disease in western Sierra Leone. *Am J Infect Control*, 2016 Nov 1, 44 (11) : 1285-1290. doi : 10.1016/j.ajic.2016.04.216.
101. Yazdanpanah Y., Horby P., van Griensven J. *et al.* Drug assessment in the Ebola virus disease epidemic in West Africa. *The Lancet Infectious Diseases*, 2015, 15 : 1258.